175464-48-9

Upstream product

• 175464-23-0 (-)-N-(3aβ,6aβ-hexahydro-6β-iodo-2-oxo-3αR,5α-methano-2H-cyclopenta[b]furan-7S-yl)-4-methylbenzenesulfonamide 
• 175464-25-2 (+)-N-(5aS-hydroxymethyl-3-oxo-3aα,6aα-cyclopent[c]furan-4βR-yl)-4-methylbenzenesulfonamide 
• 175464-24-1 (-)-3R-[[(4-methylphenyl)sulfonyl]amino]bicyclo[2.2.1]hept-5-ene-2αR carboxylic acid 
• 175464-26-3 (+)-1a,4a-bis(hydroxymethyl)-3b-[[(4-methylphenyl)sulfonyl]amino]cyclopentane-2a-carboxamide 

Downstream Products

• 175464-27-4 (+)-1,1-dimethylethyl-N-[[1α,4α-bis(hydroxymethyl)-3β-[[(4-methylphenyl)sulfonyl]amino]cyclopentan-2α-yl]methyl]carbamate 
• 165874-34-0 hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopenta[c]pyrrol-4α-amine 
• 175670-09-4 (+)-N-(hexahydro-2,5β-methano-1H-3aS,3aα,6aα-cyclopenta[c]pyrrol-4α-yl)-4-methylbenzenesulfonamide 
• 175464-49-0 C₃₄H₄₄N₂O₁₀S₃ 

Relevant academic research and scientific papers

Enantioselective synthesis of dual 5-HT4/5-HT3 serotonergic azanoradamantane SC-52491

A racemic synthesis of azanoradamantane (±)-3 was accomplished via Yamamoto's MAD-catalyzed Diels-Alder protocol. Subsequently, a scalable asymmetric synthesis of azanoradamantane benzamide SC-52491 was carried out employing Helmchen's asymmetric Diels-Alder methodology to construct all four contiguous asymmetric centers with the correct relative stereochemistry and in 99.3% e.e.